BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 1904039)

  • 1. [Contraception by cyclic treatment with buserelin and progesterone].
    Wieacker P; Breckwoldt M; Greif M; Geisthövel F
    Geburtshilfe Frauenheilkd; 1991 Feb; 51(2):135-9. PubMed ID: 1904039
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fourteen-day versus twenty-one-day regimens of intermittent intranasal luteinizing hormone-releasing hormone agonist combined with an oral progestogen as antiovulatory contraceptive approach.
    Lemay A; Faure N
    J Clin Endocrinol Metab; 1986 Dec; 63(6):1379-85. PubMed ID: 2946711
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cyclic administration of an LHRH analogue and of progesterone in risk patients to oral contraceptives.
    Geisthoevel F; Jenne D; Wieacker P; Breckwoldt M
    Contraception; 1987 Oct; 36(4):459-69. PubMed ID: 3127113
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ovarian sonographic findings during intermittent intranasal luteinizing hormone-releasing hormone agonist sequentially combined with an oral progestogen as antiovulatory contraceptive approach.
    Lemay A; Faure N; Bastide A
    Fertil Steril; 1987 Jan; 47(1):60-6. PubMed ID: 2947818
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chronic treatment with the gonadotropin-releasing hormone agonist D-Ser(TBU)6-EA10-LRH for contraception in women and men.
    Nillius SJ; Bergquist C; Wide L
    Int J Fertil; 1980; 25(3):239-46. PubMed ID: 6108935
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chronic treatment with a LH-RH-agonist: a new contraceptive method?
    Schmidt-Gollwitzer M; Hardt W; Schmidt-Gollwitzer K; Nevinny-Stickel J
    Acta Eur Fertil; 1981 Sep; 12(3):275-6. PubMed ID: 6803498
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Ultrasonic and hormonal monitoring of the ovaries during mini-dose oral contraception].
    Doyen J; Schaaps JP; Lambotte R
    Contracept Fertil Sex (Paris); 1987 May; 15(5):529-33. PubMed ID: 12268693
    [TBL] [Abstract][Full Text] [Related]  

  • 8. GnRH agonist as luteal phase support in assisted reproduction technique cycles: results of a pilot study.
    Pirard C; Donnez J; Loumaye E
    Hum Reprod; 2006 Jul; 21(7):1894-900. PubMed ID: 16556673
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Ovarian suppression by the GnRH analog buserelin in the treatment of endometriosis. Clinical, biochemical and pelviscopic studies].
    Raitz von Frentz M; Schweppe KW
    Geburtshilfe Frauenheilkd; 1990 Aug; 50(8):634-9. PubMed ID: 2145192
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interference in follicular maturation following acute intranasal LH-RH agonist administration during mid and late follicular phase.
    Lemay A; Faure N
    Int J Fertil; 1988; 33(1):60-7. PubMed ID: 2896176
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinical and biochemical results during the treatment with marvelon, a new oral contraceptive (author's transl)].
    Mall-Haefeli M; Werner-Zodrow I; Huber P; Weijers MJ
    Geburtshilfe Frauenheilkd; 1982 Mar; 42(3):215-22. PubMed ID: 6210600
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Plasma concentrations of LH and of sex steroids during the normal menstrual cycle and during contraceptive treatment].
    Bayard F; Louvet JP; Moatti JP; Smilovici W; Duguet L; Boulard C
    J Gynecol Obstet Biol Reprod (Paris); 1975; 4(7):915-26. PubMed ID: 767402
    [TBL] [Abstract][Full Text] [Related]  

  • 13. GnRH agonist as novel luteal support: results of a randomized, parallel group, feasibility study using intranasal administration of buserelin.
    Pirard C; Donnez J; Loumaye E
    Hum Reprod; 2005 Jul; 20(7):1798-804. PubMed ID: 15890740
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and efficacy of low dose hCG for luteal support after triggering ovulation with a GnRH agonist in cases of polyfollicular development.
    Krause BT; Ohlinger R
    Eur J Obstet Gynecol Reprod Biol; 2006 May; 126(1):87-92. PubMed ID: 16377065
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Individualization of low-dose oral contraceptives. Pharmacological principles and practical indications for oral contraceptives].
    Cianci A; De Leo V
    Minerva Ginecol; 2007 Aug; 59(4):415-25. PubMed ID: 17923832
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Contraception with pure, synthetic progestogens of the norpregnane group, a new approach for the future?].
    Rozenbaum H
    Contracept Fertil Sex (Paris); 1986 Jun; 14(6):577-81. PubMed ID: 12341096
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cyclic and individualized administration of gonadotropin-releasing hormone agonists plus progestogens: an alternative protocol for contraception.
    Chryssikopoulos A; Phocas I; Rizos D; Kontoravdis A
    Gynecol Endocrinol; 1997 Apr; 11(2):119-26. PubMed ID: 9174853
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The pills: oral contraceptives and other hormones.
    Kome P
    Homemak Mag; 1977 May; 12(4):33-4. PubMed ID: 12308626
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Treatment of endometriosis with the GnRH agonist buserelin (Suprecur): a multicenter study].
    Schindler AE; Bühler K; Mettler L; Fuchs U; Cirkel U; Ochs H; Schweppe KW; Koch R
    Geburtshilfe Frauenheilkd; 1994 Oct; 54(10):569-73. PubMed ID: 8001754
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The efficacy of gestoden (delta 15-d-norgestrel) as ovulation inhibitor (author's transl)].
    Schneider WH; Schmid R; Spona J
    Wien Klin Wochenschr; 1981 Oct; 93(19):601-4. PubMed ID: 6798765
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.